- Eli Lilly shares surged over 5% after President Trump announced a new plan aiming to reduce U.S. drug prices.
- Pfizer agreed to the plan, committing to cut drug prices by up to 85% and receiving a three-year exemption from tariffs.
- Analysts indicated that the agreement sets a framework for other drug manufacturers to cooperate with policy changes while averting aggressive regulations.
- The overall pharmaceutical sector rallied, with the S&P 500 Pharmaceuticals Index rising nearly 4% and Pfizer gaining almost 7% in its strongest session in four years.
- Experts noted that unless insurance reforms follow, the direct-to-consumer “TrumpRx” program may not significantly lower consumer medication costs.
Eli Lilly stock climbed by more than 5% on Tuesday following the announcement of a new initiative from U.S. President Donald Trump intended to reduce domestic drug prices. The plan involves a direct-to-consumer website called “TrumpRx” and a pricing agreement with Pfizer.
Pfizer became the first drug company to accept the administration’s proposal, agreeing to reduce medication prices by as much as 85%. In return, Pfizer secured a three-year waiver from pharmaceutical tariffs. According to a Bloomberg report, analysts said this structure could become a template for other companies, such as Eli Lilly, to balance cooperation without facing more stringent price controls.
BMO Capital Markets analyst Evan Seigerman stated in the Bloomberg report that the agreement provides a political win for the administration, avoiding direct regulatory measures. Cantor analyst Carter Gould added that the spike in pharma stocks reflected investor optimism, since the policy moves appear more symbolic than disruptive to earnings. Pfizer’s announcement did not alter its earnings guidance, easing investor concerns over regulatory threats.
The S&P 500 Pharmaceuticals Index rose nearly 4%, while Eli Lilly posted its strongest daily gain in over a month. Pfizer shares jumped nearly 7%, the firm’s largest one-day increase in almost four years.
Raymond James health policy analyst Chris Meekins commented via CNN that the TrumpRx plan is unlikely to reduce patient expenses significantly unless insurance practices also change. “If the administration’s steps end here, this will be seen as a win for the pharmaceutical industry,” he said.
Futurum Equities strategist Shay Baloor suggested that eliminating middlemen through the TrumpRx platform could negatively affect insurance companies and pharmacy benefit managers. Baloor identified UnitedHealth, Cigna, and Walgreens as possibly impacted, while naming Hims & Hers Health as a potential beneficiary.
Eli Lilly confirmed ongoing talks with the administration to improve patient access, reaffirming its support for increased affordability. The company has not shared specifics but emphasized efforts to align with Trump’s “Most Favored Nation” pricing directive, which aims to bring U.S. drug prices closer to international levels.
According to Commerce Secretary Howard Lutnick, negotiations with major pharmaceutical companies continue. President Trump described the measures as a step toward addressing global disparities in drug pricing.
Retail sentiment toward Eli Lilly was positive, and enthusiasm for Pfizer was high among investors. Eli Lilly has declined 0.6% so far in 2025.
Previous Articles:
- MEXC Ventures Boosts Ethena Investment to $66M as USDe Soars
- US Shutdown Threat Freezes Crypto Bill as Bitcoin Rally Stalls
- SEC’s Hester Peirce Champions Crypto Innovation at Black Summit
- Ripple CTO David Schwartz Steps Down, Joins Board for New Role
- Jim Cramer Calls Bitcoin ‘Insurance’ Against $37T US Debt Crisis
